Our Solution
Using seminal fluid as a sample source; develop a screening test that can accurately determine if an asymptomatic patient has no cancer, indolent cancer, or aggressive cancer.
A Diverse Biomarker Panel
A broad range of biomarkers have been described that are able to detect cancer and discriminate between indolent and aggressive cancer. Gregor utilizes a combination of Methylated DNA, proteins, and microparticles. Gregor leverages the most promising combination of these biomarkers and methods to screen for prostate cancer.
Why Seminal Fluid?
The prostate produces about 30% of the total volume of seminal fluid; thus giving it the distinct advantage of having direct, non-invasive access to abundant prostate cancer biomarkers. These important biomarkers would be undetectable at the same stage of cancer development by other sample types such as blood or urine.
Furthermore, our test will be available to be collected in the comfort of ones own home and shipped back to the lab. The ease of use and widespread availability of this test will allow more men to be tested an
Sample Stability
Gregor has developed a proprietary system to maintain biomarker stability in the seminal fluid. This will allow samples to be collected in the comfort of the patient's home and shipped back to Gregor's laboratory. The sample stability system will allow the prostate cancer screening test to be used by men in even the most remote areas.
OUR MISSION
Impact Life
We strive to make an impact on lives that can be saved, to have a positive impact on the lives of our patients, physicians, partners and employees.
Do What's Right
We will continue to always do what's right.
Innovate Together
We are building a better test to screen for and determine the aggressiveness of prostate cancer.
Build Community
Only with the community around us can we bring this screening test to the forefront and help more men get tested.
